CML Alliance^™ Treatment Support Program

Novartis, the global leader in Ph+ CML therapy, has been working with healthcare professionals and patients worldwide for more than 5 years to improve the treatment of Ph+ CML.

Novartis introduces CML Alliance™, a unique support program designed to help healthcare professionals optimize outcomes in Ph+ CML patients.